Evidence map›Paper›PMID 19023137›Full record

ArticleJournal of lipid research2009

The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis.

David Masson, Xian-Cheng Jiang, Laurent Lagrost, Alan R Tall

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Recent advances in carotenoid absorption, distribution, and elimination.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Lipid Metabolism in Tumor-Associated Myeloid-Derived Suppressor Cells.Advances in experimental medicine and biology · 2021
    Article
  12. Article
  13. Article
  14. Revisiting the Role of LXRs in PUFA Metabolism and Phospholipid Homeostasis.International journal of molecular sciences · 2019
    Review
  15. Article
  16. Article
  17. Structural basis of the lipid transfer mechanism of phospholipid transfer protein (PLTP).Biochimica et biophysica acta. Molecular and cell biology of lipids · 2018
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

David MassonDivision of Molecular Medicine, Department of Medicine, Columbia University, New York, NY 10032, USA. dm2561@columbia.edu
Xian-Cheng Jiang
Laurent Lagrost
Alan R Tall
Columbia University · USSUNY Downstate Health Sciences University · USUniversité de Bourgogne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The plasma lipid transfer proteins promote the exchange of neutral lipids and phospholipids between the plasma lipoproteins. Cholesteryl ester transfer protein (CETP) facilitates the removal of cholesteryl esters from HDL and thus reduces HDL levels, while phospholipid transfer protein (PLTP) promotes the transfer of phospholipids from triglyceride-rich lipoproteins into HDL and increases HDL levels. Studies in transgenic mouse models and in humans with rare genetic deficiencies (CETP) or common genetic variants (CETP and PLTP) highlight the central role of these molecules in regulating HDL levels. Human CETP deficiency is associated with dramatic elevations of HDL cholesterol and apolipoprotein A-I levels, while PLTP variants with increased expression are associated with higher HDL levels. A recent meta-analysis suggests that common CETP alleles causing reduced CETP and increased HDL levels are associated with reduced coronary heart disease. The failure of a clinical trial with the CETP inhibitor torcetrapib may have been related in part to off-target toxicity. Ongoing phase 3 clinical trials with other CETP inhibitors may help to clarify if this strategy can ultimately be successful in the treatment of atherosclerosis.

Indexed as

AnimalsAtherosclerosisCarrier ProteinsHumansLipoproteinsPhospholipidsPolymorphism, GeneticCarrier Proteinslipid transfer proteinLipoproteinsPhospholipids

Identifiers

PMID19023137
PMCPMC2674750
OpenAlexW2016936415

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.